533 related articles for article (PubMed ID: 20862329)
1. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease.
Cruchaga C; Kauwe JS; Mayo K; Spiegel N; Bertelsen S; Nowotny P; Shah AR; Abraham R; Hollingworth P; Harold D; Owen MM; Williams J; Lovestone S; Peskind ER; Li G; Leverenz JB; Galasko D; ; Morris JC; Fagan AM; Holtzman DM; Goate AM
PLoS Genet; 2010 Sep; 6(9):e1001101. PubMed ID: 20862329
[TBL] [Abstract][Full Text] [Related]
2. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.
Cruchaga C; Kauwe JS; Harari O; Jin SC; Cai Y; Karch CM; Benitez BA; Jeng AT; Skorupa T; Carrell D; Bertelsen S; Bailey M; McKean D; Shulman JM; De Jager PL; Chibnik L; Bennett DA; Arnold SE; Harold D; Sims R; Gerrish A; Williams J; Van Deerlin VM; Lee VM; Shaw LM; Trojanowski JQ; Haines JL; Mayeux R; Pericak-Vance MA; Farrer LA; Schellenberg GD; Peskind ER; Galasko D; Fagan AM; Holtzman DM; Morris JC; ; ; ; Goate AM
Neuron; 2013 Apr; 78(2):256-68. PubMed ID: 23562540
[TBL] [Abstract][Full Text] [Related]
3. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition.
Kauwe JS; Cruchaga C; Mayo K; Fenoglio C; Bertelsen S; Nowotny P; Galimberti D; Scarpini E; Morris JC; Fagan AM; Holtzman DM; Goate AM
Proc Natl Acad Sci U S A; 2008 Jun; 105(23):8050-4. PubMed ID: 18541914
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels.
Maxwell TJ; Corcoran C; Del-Aguila JL; Budde JP; Deming Y; Cruchaga C; Goate AM; Kauwe JSK;
Alzheimers Res Ther; 2018 Aug; 10(1):86. PubMed ID: 30153862
[TBL] [Abstract][Full Text] [Related]
5. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
6. Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.
Elias-Sonnenschein LS; Helisalmi S; Natunen T; Hall A; Paajanen T; Herukka SK; Laitinen M; Remes AM; Koivisto AM; Mattila KM; Lehtimäki T; Verhey FR; Visser PJ; Soininen H; Hiltunen M
PLoS One; 2013; 8(4):e59676. PubMed ID: 23573206
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.
Han MR; Schellenberg GD; Wang LS;
BMC Neurol; 2010 Oct; 10():90. PubMed ID: 20932310
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.
Deming Y; Li Z; Kapoor M; Harari O; Del-Aguila JL; Black K; Carrell D; Cai Y; Fernandez MV; Budde J; Ma S; Saef B; Howells B; Huang KL; Bertelsen S; Fagan AM; Holtzman DM; Morris JC; Kim S; Saykin AJ; De Jager PL; Albert M; Moghekar A; O'Brien R; Riemenschneider M; Petersen RC; Blennow K; Zetterberg H; Minthon L; Van Deerlin VM; Lee VM; Shaw LM; Trojanowski JQ; Schellenberg G; Haines JL; Mayeux R; Pericak-Vance MA; Farrer LA; Peskind ER; Li G; Di Narzo AF; ; ; Kauwe JS; Goate AM; Cruchaga C
Acta Neuropathol; 2017 May; 133(5):839-856. PubMed ID: 28247064
[TBL] [Abstract][Full Text] [Related]
9. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
10. Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: the Cache County Dementia Progression Study.
Peterson D; Munger C; Crowley J; Corcoran C; Cruchaga C; Goate AM; Norton MC; Green RC; Munger RG; Breitner JC; Welsh-Bohmer KA; Lyketsos C; Tschanz J; Kauwe JS;
Alzheimers Dement; 2014 May; 10(3):366-71. PubMed ID: 23727081
[TBL] [Abstract][Full Text] [Related]
11. Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease.
Kauwe JS; Cruchaga C; Karch CM; Sadler B; Lee M; Mayo K; Latu W; Su'a M; Fagan AM; Holtzman DM; Morris JC; ; Goate AM
PLoS One; 2011 Feb; 6(2):e15918. PubMed ID: 21347408
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
Ramos de Matos M; Ferreira C; Herukka SK; Soininen H; Janeiro A; Santana I; Baldeiras I; Almeida MR; Lleó A; Dols-Icardo O; Alcolea D; Benussi L; Binetti G; Paterlini A; Ghidoni R; Nacmias B; Meulenbroek O; van Waalwijk van Doorn LJC; Kuiperi HBJ; Hausner L; Waldemar G; Simonsen AH; Tsolaki M; Gkatzima O; Resende de Oliveira C; Verbeek MM; Clarimon J; Hiltunen M; de Mendonça A; Martins M
J Alzheimers Dis; 2018; 66(2):639-652. PubMed ID: 30320580
[TBL] [Abstract][Full Text] [Related]
13. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
14. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.
Snider BJ; Fagan AM; Roe C; Shah AR; Grant EA; Xiong C; Morris JC; Holtzman DM
Arch Neurol; 2009 May; 66(5):638-45. PubMed ID: 19433664
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
17. The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels.
Schjeide BM; Schnack C; Lambert JC; Lill CM; Kirchheiner J; Tumani H; Otto M; Tanzi RE; Lehrach H; Amouyel P; von Arnim CA; Bertram L
Arch Gen Psychiatry; 2011 Feb; 68(2):207-13. PubMed ID: 21300948
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.
Petrie EC; Cross DJ; Galasko D; Schellenberg GD; Raskind MA; Peskind ER; Minoshima S
Arch Neurol; 2009 May; 66(5):632-7. PubMed ID: 19433663
[TBL] [Abstract][Full Text] [Related]
19. Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function.
Kettunen P; Larsson S; Holmgren S; Olsson S; Minthon L; Zetterberg H; Blennow K; Nilsson S; Sjölander A
J Alzheimers Dis; 2015; 44(4):1313-22. PubMed ID: 25420549
[TBL] [Abstract][Full Text] [Related]
20. An Integrated Bioinformatics Approach for Identifying Genetic Markers that Predict Cerebrospinal Fluid Biomarker p-tau181/Aβ1-42 Ratio in ApoE4-Negative Mild Cognitive Impairment Patients.
Sun Y; Bresell A; Rantalainen M; Höglund K; Lebouvier T; Salter H;
J Alzheimers Dis; 2015; 45(4):1061-76. PubMed ID: 25720397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
